References
- Aspinall MG, Hamermesh RG (2007). Realizing the promise of personalized medicine. Harv Bus Rev, 85,117-65.
- Amoui M, Akbari ME, Tajeddini A, et al (2012). Value of sentinel lymph node biopsy in breast cancer surgery with simple pathology facilities-An Iranian local experience with a review of potential causes of false negative results. Asian Pac J Cancer Prev, 13, 5385-89. https://doi.org/10.7314/APJCP.2012.13.11.5385
- Avram AM (2012). Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification. J Nucl Med, 53, 754-64.
- Blankespoor SC, Wu X, Kalki JK (1996). Attenuation correction of SPECT using X-ray CT on an emission-transmission CT system: myocardial perfusion assessment. IEEE Trans Nucl Sci, 43, 2263-74. https://doi.org/10.1109/23.531891
- Buck A, Nekolla S, Ziegler S, et al (2008). SPECT/CT. J Nucl Med, 49, 1305-19. https://doi.org/10.2967/jnumed.107.050195
- Bockisch Am, Freudenberg LS, Schmidt D, Kuwert T (2008). Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging. Semin Nucl Med, 39, 276-89.
- Ben-Haim S, Ell P (2009). 18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response. J Nucl Med, 50, 88-99.
- Beyer T, Freudenberg LS, Townsend DW, Czernin J (2011). The future of hybrid imaging-part 1: hybrid imaging technologies and SPECT/CT. Insights Imaging, 2, 161-69. https://doi.org/10.1007/s13244-010-0063-2
- Beyer T, Townsend DW, Czernin J, Freudenberg LS (2011). The future of hybrid imaging-part 2: PET/CT. Insights Imaging, 2, 225-34. https://doi.org/10.1007/s13244-011-0069-4
- Castellino RA, Hilton S, O'Brien P, et al (1996). Non-Hodgkin lymphoma: contribution of chest CT in the initial staging solution. Radiology, 199, 129-32. https://doi.org/10.1148/radiology.199.1.8633134
- Czernin J, Allen-Auerbach M, Schelbert H (2007). Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med, 48, 78-88.
- Delso G, Furst S, Jakoby B, et al (2011). Performance measurements of the siemens mMR integrated whole-body PET/MR scanner. J Nucl Med, 52, 1-9. https://doi.org/10.2967/jnumed.110.076018
- Even-Sapir E, Lerman H, Lievshitz G, et al (2003). Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med, 44, 1413-20.
- Fontaine R, Belanger F, Viscogliosi N, et al (2009). "The hardware and signal processing architecture of LabPETTM, a small animal APD-based digital PET scanner. IEEE Trans Nucl Sci, 56, 3-9. https://doi.org/10.1109/TNS.2008.2007485
- Flohr TG, Ernst K, Thomas A, et al (2010). Pushing the envelope: new computed tomography techniques for cardiothoracic imaging. J Thorac Imaging, 25, 100-11. https://doi.org/10.1097/RTI.0b013e3181d7e898
- Hutton BF, Braun M, Thurfjell L, Lau DYH (2002). Image registration: an essential tool for nuclear medicine. Eur J Nucl Med Mol Imaging, 29, 559-77. https://doi.org/10.1007/s00259-001-0700-6
- Inaoka T, Takahashi K, Mineta M, et al (2007). Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology, 243, 869-76. https://doi.org/10.1148/radiol.2433060797
- Jaszczak RJ, Coleman RE, Lim CB (1980). SPECT: Single photon emission computed tomography. IEEE Tran Nucl Sci, 27, 1137-53. https://doi.org/10.1109/TNS.1980.4330986
- Keidar Z, Israel O, Krausz Y (2003). SPECT/CT in tumor imaging: technical aspects and clinical applications. Semin Nucl Med, 33, 205-18. https://doi.org/10.1053/snuc.2003.127310
- Kaya AO, Coskun U, Unlu M, et al (2008). Whole body 18FDG PET/CT imaging in the detection of primary tumors in patients with a metastatic carcinoma of unknown origin. Asian Pac J Cancer Prev, 9, 683-86.
- Lerman H, Metser U, Lievshitz G, et al (2006). Lymphoscintigraphic sentinel node identi?cation in patients with breast cancer: the roll of SPECT-CT. Eur J Nucl Med Mol Imaging, 33, 329-37.
- Lerman H, Lievshitz G, Zak O, et al (2007). Even-Sapir E. improved sentinel node identification by SPECT/CT in Overweight Patients with Breast Cancer. J Nucl Med, 48, 201-06.
- Liu J, Yang X, Li F, Wang X, Jiang X (2011). Preliminary study of whole-body diffusion-weighted imaging in detecting pulmonary metastatic lesions from clear cell renal cell carcinoma: comparison with CT. Acta Radiol, 52, 954-63. https://doi.org/10.1258/ar.2011.110121
- Liu NB, Zhu L, Li MH, Sun XR, et al (2013). Diagnostic value of 18F-FDG PET/CT in comparison to bone scintigraphy, CT and 18F-FDG PET for the detection of bone Metastasis. Asian Pac J Cancer Prev, 14, 3647-52. https://doi.org/10.7314/APJCP.2013.14.6.3647
- Mian C, Barollo S, Pennelli G, et al (2008). Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf), 68, 108-16. https://doi.org/10.1111/j.1365-2265.2007.03008.x
- Moy L, Noz ME, Maguire GQ et al (2010). Role of fusion of prone FDG-PET and magnetic resonance imaging of the breasts in the evaluation of breast cancer. Breast J, 16, 369-76.
-
Mainenti PP, Iodice D, Segreto S, et al (2011). Colorectal cancer and
$^{18}$ FDG-PET/CT: what about adding the T to the N parameter in loco-regional staging? World J Gastroenterol, 17, 1427-33. https://doi.org/10.3748/wjg.v17.i11.1427 - Mansi L, Ciarmiello A, Cuccurullo V (2012). PET/MRI and the revolution of the third eye. Eur J Nucl Med Mol Imaging, 39, 1519-24. https://doi.org/10.1007/s00259-012-2185-x
- Papathanassiou D, Liehn JC (2008). The growing development of multimodality imaging in oncology. Critical Rev Oncol Hematol, 68, 60-5. https://doi.org/10.1016/j.critrevonc.2008.04.003
- Petronis JD, Regan F, Lin K (1998). Indium-111 capromab pendetide (prostascint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med, 23, 672-77. https://doi.org/10.1097/00003072-199810000-00005
- Park JW, Kim JH, Kim SK, et al (2008). Choi JI, Lee WJ, Kim CM, Nam BH. a prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med, 49, 1912-21. https://doi.org/10.2967/jnumed.108.055087
- Pichler BJ, Kolb A, Nagele T, Schlemmer HP (2010). PET/MRI: Paving the Way for the Next Generation of Clinical Multimodality Imaging Applications. J Nucl Med, 51, 333-36. https://doi.org/10.2967/jnumed.109.061853
- Pace L, Nicolai E, Aiello M, Catalano OA, Salvatore M (2013). Whole-body PET/MRI in oncology: current status and clinical Applications. Clin Transl Imaging, 1, 31-44. https://doi.org/10.1007/s40336-013-0012-4
- Rufini V, Calcagni ML, Baum RP (2006). Imaging of neuroendocrine tumors. Semin Nucl Med, 36, 228-47. https://doi.org/10.1053/j.semnuclmed.2006.03.007
- Sodee DB, Sodee AE, Bakale G (2007). Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med, 37, 17-28. https://doi.org/10.1053/j.semnuclmed.2006.07.002
- Strauss LG, Conti PS (1991). The application of PET in clinical oncology. J Nucl Med, 32, 623-48.
- Shao Y, Cherry SR, Farahani K, et al (1997). Simultaneous PET and MR imaging. Phys Med Biol, 42, 1965-70. https://doi.org/10.1088/0031-9155/42/10/010
- Schmidt GP, Schoenberg SO, Schmid R, et al (2007). Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol, 17, 939-49. https://doi.org/10.1007/s00330-006-0361-8
- Townsend D (2008). Multimodality imaging of structure and function. Phys Med Biol, 53, R1-R39 https://doi.org/10.1088/0031-9155/53/4/R01
- Tateishi U, Hosono A, Makimoto A, et al (2009). Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med, 23, 155-61. https://doi.org/10.1007/s12149-008-0219-z
- Thamnirat K, Utamakul C, Chamroonrat V, et al (2015). Factors affecting disease-free status of differentiated thyroid carcinoma patients. Asian Pac J Cancer Prev, 16, 737-40. https://doi.org/10.7314/APJCP.2015.16.2.737
- Vandecaveye V, De Keyzer F, Vander PV, et al (2009). Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology, 251, 134-46. https://doi.org/10.1148/radiol.2511080128
- Watson CC, Casey ME, Bendriem B, et al (2005). Optimizing injected dose in clinical PET by accurately modeling the counting-rate response functions specific to individual patient scans. J Nucl Med, 46, 1825-34.
- Wahl RL, Quint LE, Cieslak RD, al (1993). "Anatometabolic" tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med, 34, 1190-97.
- Wagner HN. (2005). A personal history of nuclear medicine. Springer, London .
- www-pub.iaea.org/MTCD/publications/PDF/te_1597_web.pdf. (visited 20.2.2014).
- Zaman M, Fatima N, Sajjad Z, Zaman Unaiza (2014). Whole body simultaneous PET/MRI: One-stop-shop? JPMA, 64, 201-05.